Is Lisata Therapeutics, Inc. (LSTA) a Buy, Sell, or Hold?
NASDAQ : LSTA
Lisata Therapeutics, Inc.
$3.595 USD
$0.1 (2.71%)
- Volume
- 64.29K
- Average Volume
- 103.21K
- Market Capitalization
- $32.74M
- P/E Ratio
- -1.93
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.07
- Year Low
- $1.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.23
| Source | Headline |
|---|---|
|
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ: LSTA) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. globenewswire.com - 2026-06-26 11:08:00 |
|
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 15, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lisata Therapeutics, Inc. ("Lisata Therapeutics" or the "Company") (NASDAQ - LSTA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Kuva Labs, Inc. ("Kuva") for $4.00 per share in cash plus two non-tradeable contingent value rights (CVRs), payable as follows: (1) $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and (2) $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction. The investigation concerns whether the Lisata Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. newsfilecorp.com - 2026-06-15 16:53:00 |
|
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones. proactiveinvestors.com - 2026-06-10 09:38:03 |
|
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones globenewswire.com - 2026-06-10 08:00:00 |
|
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value... proactiveinvestors.com - 2026-06-10 05:36:00 |
|
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. globenewswire.com - 2026-05-04 14:48:00 |
|
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. globenewswire.com - 2026-05-04 13:45:05 |
